Conroe · Houston · Fulshear · Katy · Kingwood  |  Telehealth in TX, NC & SC — Care From HomeCall or text 713-BOTOX-ME (713-268-6963)

Home / Treatment Library / Jeuveau®

Neurotoxin

Jeuveau®

Precision wrinkle treatment. A clear, evidence-aware guide to candidacy, treatment, recovery, limitations and next steps.

Evidence reviewed July 30, 2026
SettingIn-office treatment
PricingFrom $14 per unit
Provider reviewIndividualized
Confident woman in an elegant, softly lit Identity Aesthetics setting
Confidence, refined

Natural-looking results begin with an individualized plan

Your anatomy, expression and goals guide every recommendation—so the result still feels unmistakably like you.

The short answer

What is Jeuveau®?

Jeuveau® is prabotulinumtoxinA-xvfs, and it is the only one of the four that exists purely for aesthetics. Its FDA indication is the temporary improvement in the appearance of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity in adults — and its boxed warning states plainly that it is not approved for spasticity or any condition other than glabellar lines. Where the other three carry long lists of medical indications, Jeuveau® was developed and approved for this one cosmetic use.

Concerns it may address

  • Frown lines between the brows — the single labeled use
  • Adults seeking treatment of the glabellar complex specifically
  • Patients comparing toxin options for the frown-line area
  • Anyone who wants the product choice kept narrow and on label
Choosing between toxins

How Jeuveau® differs from Botox®, Dysport and Xeomin

Jeuveau® is the narrowest product of the four, and that narrowness is the point rather than a limitation.

It is cosmetic-only by design

Botox® Cosmetic, Dysport® and Xeomin® all share a molecule with therapeutic products carrying indications for conditions like spasticity, cervical dystonia and chronic sialorrhea. Jeuveau® does not. Its label is one cosmetic indication, and its boxed warning says so explicitly.

Its label covers the glabella alone

The indication names the corrugator and procerus muscles — the frown-line complex between the brows. Xeomin® and Botox® Cosmetic carry broader cosmetic labeling across the upper face.

Its units are its own, like every other toxin

A Jeuveau® unit is not a Botox®, Dysport® or Xeomin® unit. If you are moving to Jeuveau® from another product, the provider builds a new dose from your anatomy and prior response rather than converting a number.

Product selection is a clinical decision made with you at consultation. Nothing here is a recommendation for a specific product, and no toxin can be dosed from a web page.

Candidacy

Who may—or may not—be a candidate

Who may be considered

Adults who want the frown lines between their brows treated, and nothing else on this visit. Jeuveau®’s indication is the glabellar complex — the corrugator and procerus muscles — and its boxed warning states plainly that it is not approved for spasticity or any condition other than glabellar lines. A good candidate understands the result is temporary, that asymmetry is possible, and that a narrow label is a reason for confidence in that area rather than a limitation.

When treatment may not be appropriate

Treatment may be deferred for pregnancy or breastfeeding, active infection at an injection site, known allergy to an ingredient, certain neuromuscular disorders, or symptoms that require medical evaluation. Tell the provider about all medications, supplements, prior toxin products and any swallowing or breathing problems. If your goal is the forehead, the outer eye or the neck, Jeuveau® is not the product for it and your provider will say so.

At a glance

Treatment facts

These are practical planning ranges, not promises. Your consultation determines the exact plan.

Treatment time
About 15–30 minutes
Comfort / anesthesia
Brief pinches; topical numbing is usually optional
Typical downtime
Usually minimal; small bumps or bruising may occur
When changes may appear
Often begins within several days; allow up to 2 weeks to assess
How long results may last
Commonly about 3–4 months
Treatments commonly considered
One visit, then reassessment or maintenance as appropriate
Your visit

What happens during treatment

Assess the glabella

Your provider reviews health history, prior toxin use and how the corrugator and procerus muscles pull when you frown. This is the area Jeuveau® is approved for.

Treat the area

Expression patterns are mapped and the skin is cleansed. Small measured injections are placed with a fine needle, dosed from your own muscle strength rather than converted from another product.

Review and follow up

You receive aftercare and a follow-up window. Do not judge symmetry before the product has had time to settle, which can take up to two weeks.

Informed choice

Important risks, limitations and alternatives

Risks & limitations

Expected effects can include temporary redness, tenderness, bruising, swelling or asymmetry. Every botulinum toxin product carries a boxed warning about distant spread of toxin effect: rare but serious risks include swallowing, speaking or breathing difficulty. Units of one product cannot be compared to or converted into units of another. Treatment cannot be guaranteed and must follow an individualized examination.

Alternatives to discuss

  • No treatment or skincare for surface-quality goals
  • Another FDA-approved botulinum toxin, recognizing units cannot be converted directly
  • Dermal filler or biostimulator when volume—not muscle movement—is the primary concern
  • Laser or resurfacing treatments for pigment, texture and fine etched lines
Clinical judgment

Why provider experience matters

Small differences in depth, angle, dose and muscle selection change the outcome. An experienced medical injector can distinguish dynamic lines from volume loss, protect brow and eyelid function, plan around asymmetry and recognize complications early.

Identity Aesthetics approach

  • Diagnosis and anatomy before a product or device
  • Conservative planning with candid limitations
  • Licensed-provider supervision and complication readiness
  • In-office and telehealth boundaries stated clearly
Access & cost

In-office versus telehealth

Treatment is in-office only. Telehealth can answer general questions, but facial examination, consent and injections occur at an Identity Aesthetics location.

Pricing: From $14 per unit. Final cost depends on the number of units selected after assessment. Always ask about current promotions and volume savings.

Common questions

Jeuveau® FAQ

Will I look frozen?
The goal can be subtle softening with natural movement. Your desired finish, anatomy and dose are discussed before treatment; no injector can promise an exact appearance.
Can I switch toxin brands?
Sometimes, but each product has its own formulation and labeled dosing. Units are not interchangeable, so the provider plans a new dose rather than using a simple conversion.
When should I call the office?
Contact the practice promptly for concerning weakness, eyelid or brow changes, severe headache, vision changes or any unexpected symptom. Seek emergency care for trouble breathing, swallowing or speaking.

Sources & medical review

  1. FDA Prescribing Information — Jeuveau

Medical-content evidence review: July 30, 2026. Content is written for patient education and structured from current primary regulatory, labeling and professional sources. It has not been individualized to your medical history. Product labeling and guidance can change; a licensed Identity Aesthetics provider confirms current suitability, informed consent and treatment details before care.

Your next step

Make an informed plan

Bring your goals, questions, medication list and prior treatment history. We will help you decide whether Jeuveau®—or an alternative—makes sense.

Continue Exploring

Move from information to the right next step.

Explore connected treatment guidance, meet the clinical team or begin a personalized consultation.

Prepared byIdentity Aesthetics Clinical Editorial Team

Patient education developed from primary regulatory, labeling and professional sources.

Medically reviewed byDallas Alvey, MD, DDS

Chief Medical Officer – Texas · Aesthetic medicine, hormone optimization and peptide therapy.